The impact of rifaximin-α on the hospital resource use associated with the management of patients with hepatic encephalopathy: a retrospective observational study (IMPRESS)
Mark Hudson(The Open University), Richard Aspinall(Queen Alexandra Hospital), Debbie L. Shawcross(King's College - North Carolina), Sushma Saksena(Royal London Hospital), Riccardo Cipelli, Michael Allison(Cambridge University Hospitals NHS Foundation Trust), Mark Wright(University Hospital Southampton NHS Foundation Trust), Paola Maggio(University of Bergamo), Amr Radwan, Rajiv Jalan(Roland Hill (United Kingdom)), Paul Richardson(University of Liverpool), Robert Przemioslo(Southmead Hospital), Elizabeth Farrington(Royal Cornwall Hospital), Stephen Ryder(Nottingham University Hospitals NHS Trust), W.J. Cash(University of Ulster), John Dillon(Mayo Clinic)
Cited by 28
Related Papers
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
|Nature|2021|1.3k
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin
|Nature Genetics|2009|1.1k
MAIT cells are activated during human viral infections
|Nature Communications|2016|526